A Phase I study of ONO-7268MX2 in patients with hepatocellular carcinoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2016
At a glance
- Drugs ONO 7268MX2 (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 15 Jul 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017.
- 27 Jan 2016 Status changed from planning to active, no longer recruiting.
- 11 Dec 2013 New trial record